Study of VIR-2218, VIR-3434, And/or PEG-IFNα in Subjects with Chronic Hepatitis B Virus Infection

Launched by VIR BIOTECHNOLOGY, INC. · Apr 21, 2021

Keywords

ClinConnect Summary

This clinical trial is studying new treatments for people with chronic hepatitis B virus (HBV) infection. Specifically, researchers want to see how safe and effective three different treatments—VIR-2218, VIR-3434, and PEG-IFNα—are for patients. If you or someone you know has been living with chronic HBV for at least six months and is between the ages of 18 and 65, you may be eligible to participate in this study, provided you have been on antiviral therapy for at least two months.

Participants in this trial will receive one or more of the study medications and will be monitored closely for any side effects and how well the treatments work. It’s important to know that certain health conditions, like severe liver disease or a history of serious allergic reactions, could exclude someone from participating. If you're interested in joining or learning more, reach out to the study team, who can provide further details and answer any questions you may have.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female ages 18 - \<66 years
• • Chronic HBV infection for \>/= 6 months
• • On NRTI therapy for \>/= 2 months at the time of screening
• Exclusion Criteria:
• • Any clinically significant chronic or acute medical condition that makes the participant unsuitable for participation
• • Significant fibrosis or cirrhosis
• • History or evidence of drug or alcohol abuse
• • History of chronic liver disease from any cause other than chronic HBV infection
• • History of hepatic decompensation
• • History of anaphylaxis
• • History of allergic reactions, hypersensitivity, or intolerance to monoclonal antibodies, antibody fragments, or any excipients of VIR-3434
• • History of immune complex disease
• • History of known contraindication to any interferon product